ArticleEuropean journal of internal medicine2019
An international perspective on hospitalized patients with viral community-acquired pneumonia.
Article in European journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2021Guideline
- Prevalence, associated factors and treatment prescriptions for community-acquired pneumonia: a cross-sectional study at the largest children's hospital in the Ashanti Region, Ghana.BMC infectious diseases · 2026Article
- Pathogen trends and paradigm shifts of respiratory infections in children: a 5-year retrospective study from Perugia.Italian journal of pediatrics · 2026Article
- Burden and Risk Factors for Coinfections in Patients with a Viral Respiratory Tract Infection.Pathogens (Basel, Switzerland) · 2024Article
- Observational
- Myosteatosis predicting risk of transition to severe COVID-19 infection.Clinical nutrition (Edinburgh, Scotland) · 2022Article
- Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.International journal of environmental research and public health · 2022Article
- A 48-Year-Old Previously Healthy Man Presenting with Acute Respiratory Distress Syndrome (ARDS), Negative Tests for SARS-CoV-2, and Positive Serology for Parainfluenza Virus Type 3 (PIV-3).The American journal of case reports · 2022Article
- Extremely Old Patients Hospitalized in Internal Medicine: What about Their Anemia?Mediterranean journal of hematology and infectious diseases · 2021Article
- Analysis of the application and efficacy of "Trinity" rehabilitation nursing in management of bronchial asthma.American journal of translational research · 2021Article
- Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia.PloS one · 2021Article
- Observational
- Clinical practice guidelines for influenza and pneumococcal vaccination: The Indian perspective.Lung India : official organ of Indian Chest Society · 2020Article
- The Clinical Characteristics and Outcomes of Adult Patients With Pneumonia Related to Three Paramyxoviruses.Frontiers in medicine · 2020Article
- Hot topics and current controversies in community-acquired pneumonia.Breathe (Sheffield, England) · 2019Review
- Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors.The Journal of infectious diseases · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 20 institutions in 24 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWho should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP.
methodsSecondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors.
results553 (14.9%) patients with CAP underwent nasal swab. Viral CAP was diagnosed in 157 (28.4%) patients. Influenza virus was isolated in 80.9% of cases. Testing frequency and viral CAP prevalence were inhomogeneous across the participating centers. Obesity (OR 1.59, 95%CI: 1.01-2.48; p = 0.043) and need for invasive mechanical ventilation (OR 1.62, 95%CI: 1.02-2.56; p = 0.040) were independently associated with viral CAP. Prevalence of empirical treatment with oseltamivir was 5.1%.
conclusionIn an international scenario, testing frequency for viruses in CAP is very low. The most common cause of viral CAP is Influenza virus. Obesity and need for invasive ventilation represent independent risk factors for viral CAP. Adherence to recommendations for treatment with oseltamivir is poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.